• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Eli Lilly lifts sales view by $2 billion on soaring weight-loss drug demand

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 30, 2024 at 08:52: AM
via Eli Lilly (LLY.N) raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and a steady ramp up of production of its weight-loss treatment Zepbound and related diabetes drug Mounjaro, lifting its shares about 7%.

article source
 




Top Bottom
Back
Quote